TNF and TNF receptor superfamily members in HIV infection: New cellular targets for therapy?

Mediators of Inflammation

Volumn 2013, Issue , 2013, Pages

  Kumar, Amit ^a   Abbas, Wasim ^a   Herbein, Georges ^a  

^a UNIVERSITÉ DE FRANCHE COMTÉ   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CD134 ANTIGEN; CD27 ANTIGEN; CD40 ANTIGEN; CD40 LIGAND; LYMPHOTOXIN BETA RECEPTOR; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR;

APOPTOSIS; DRUG ANTAGONISM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOLOGY; PHYSIOLOGY; REVIEW; SIGNAL TRANSDUCTION;

ANTIGENS, CD27; ANTIGENS, CD40; APOPTOSIS; CD40 LIGAND; HIV INFECTIONS; HUMANS; LYMPHOTOXIN BETA RECEPTOR; RECEPTORS, OX40; RECEPTORS, TUMOR NECROSIS FACTOR; SIGNAL TRANSDUCTION; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84893829335     PISSN: 09629351     EISSN: 14661861     Source Type: Journal    
DOI: 10.1155/2013/484378     Document Type: Review

References (143)

1. Carswell E. A., Old L. J., Kassel R. L., An endotoxin induced serum factor that causes necrosis of tumors. Proceedings of the National Academy of Sciences of the United States of America 1975 72 9 3666 3670 2-s2.0-0016723594
2. Beutler B., Cerami A., Cachectin and tumour necrosis factor as two sides of the same biological coin. Nature 1986 320 6063 584 588 2-s2.0-0022485610 (Pubitemid 16039134)
3. Bradley J. R., TNF-mediated inflammatory disease. Journal of Pathology 2008 214 2 149 160 2-s2.0-38549102077 10.1002/path.2287 (Pubitemid 351160153)
4. Aggarwal B. B., Gupta S. C., Kim J. H., Historical perspectives on tumor necrosis factor and its superfamily: 25 years later, a golden journey. Blood 2012 119 3 651 665 2-s2.0-84856074741 10.1182/blood-2011-04-325225
5. Moelants E. A., Mortier A., van Damme J., Proost P., Regulation of TNF-alpha with a focus on rheumatoid arthritis. Immunology & Cell Biology 2013 91 6 393 401
6. Aggarwal B. B., Signalling pathways of the TNF superfamily: a double-edged sword. Nature Reviews Immunology 2003 3 9 745 756 2-s2.0-0141465062 10.1038/nril184 (Pubitemid 41070815)
7. Herbein G., O'Brien W. A., Tumor necrosis factor (TNF)- α and TNF receptors in viral pathogenesis. Proceedings of the Society for Experimental Biology and Medicine 2000 223 3 241 257 2-s2.0-0034115960 (Pubitemid 30337778)
8. Pennica D., Nedwin G. E., Hayflick J. S., Human tumour necrosis factor: precursor structure, expression and homology to lymphotoxin. Nature 1984 312 5996 724 729 2-s2.0-0021681058 (Pubitemid 15195918)
9. Kelker H. C., Oppenhaim J. D., Stone-Wolff D., Characterization of human tumor necrosis factor produced by peripheral blood monocytes and its separation from lymphotoxin. International Journal of Cancer 1985 36 1 69 73 2-s2.0-0021866477 (Pubitemid 15028617)
10. Herbein G., Khan K. A., Is HIV infection a TNF receptor signalling-driven disease? Trends in Immunology 2008 29 2 61 67 2-s2.0-39049155167 10.1016/j.it.2007.10.008
11. Beutler B., van Huffel C., Unraveling function in the TNF ligand and receptor families. Science 1994 264 5159 667 668 2-s2.0-0028277663 (Pubitemid 24987881)
12. Black R. A., Rauch C. T., Kozlosky C. J., Peschon J. J., Slack J. L., Wolfson M. F., Castner B. J., Stocking K. L., Reddy P., Srinivasan S., Nelson N., Boiani N., Schooley K. A., Gerhart M., Davis R., Fitzner J. N., Johnson R. S., Paxton R. J., March C. J., Cerretti D. P., A metalloproteinase disintegrin that releases tumour-necrosis factor-ø from cells. Nature 1997 385 6618 729 733 2-s2.0-8044257704 10.1038/385729a0 (Pubitemid 27098094)
13. Grell M., Wajant H., Zimmermann G., Scheurich P., The type 1 receptor (CD120a) is the high-affinity receptor for soluble tumor necrosis factor. Proceedings of the National Academy of Sciences of the United States of America 1998 95 2 570 575 2-s2.0-0031882913 10.1073/pnas.95.2.570 (Pubitemid 28083784)
14. Grell M., Douni E., Wajant H., Lohden M., Clauss M., Maxeiner B., Georgopoulos S., Lesslauer W., Kollias G., Pfizenmaier K., Scheurich P. S., The transmembrane form of tumor necrosis factor is the prime activating ligand of the 80 kDa tumor necrosis factor receptor. Cell 1995 83 5 793 802 2-s2.0-0028866022
15. Hsu H., Xiong J., Goeddel D. V., The TNF receptor 1-associated protein TRADD signals cell death and NF- B activation. Cell 1995 81 4 495 504 2-s2.0-0029007855
16. Hsu H., Shu H., Pan M., Goeddel D. V., TRADD-TRAF2 and TRADD-FADD interactions define two distinct TNF receptor 1 signal transduction pathways. Cell 1996 84 2 299 308 2-s2.0-0030032106 10.1016/S0092-8674(00)80984-8 (Pubitemid 26042835)
17. DiDonato J. A., Hayakawa M., Rothwarf D. M., Zandi E., Karin M., A cytokine-responsive IkappaB kinase that activates the transcription factor NF-kappaB. Nature 1997 388 6642 548 554 (Pubitemid 27339997)
18. Mercurio F., Zhu H., Murray B. W., Shevchenko A., Bennett B. L., Li J. W., Young D. B., Barbosa M., Mann M., Manning A., Rao A., IKK-1 and IKK-2: cytokine-activated I B kinases essential for NF- B activation. Science 1997 278 5339 860 866 2-s2.0-0030685825 10.1126/science.278.5339.860 (Pubitemid 27467923)
19. Devin A., Cook A., Lin Y., Rodriguez Y., Kelliher M., Liu Z., The distinct roles of TRAF2 and RIP in IKK activation by TNF-R1: tRAF2 recruits IKK to TNF-R1 while RIP mediates IKK activation. Immunity 2000 12 4 419 429 2-s2.0-0033725155
20. Natoli G., Costanzo A., Moretti F., Fulco M., Balsano C., Levrero M., Tumor necrosis factor (TNF) receptor 1 signaling downstream of TNF receptor-associated factor 2. Nuclear factor B (NF B)-inducing kinase requirement for activation of activating protein 1 and NF B but not of c-Jun N-terminal kinase/stress-activated protein kinase. The Journal of Biological Chemistry 1997 272 42 26079 26082 2-s2.0-0030666194 10.1074/jbc.272.42.26079 (Pubitemid 27458811)
21. Grell M., Becke F. M., Wajant H., Mnnel D. N., Scheurich P., TNF receptor type 2 mediates thymocyte proliferation independently of TNF receptor type 1. European Journal of Immunology 1998 28 1 257 263 (Pubitemid 28048296)
22. Gehr G., Gentz R., Brockhaus M., Loetscher H., Lesslauer W., Both tumor necrosis factor receptor types mediate proliferative signals in human mononuclear cell activation. Journal of Immunology 1992 149 3 911 917 2-s2.0-0026771014
23. Zheng L., Fisher O., Miller R. E., Peschon J., Lynch D. H., Lenardo M. J., Induction of apoptosis in mature T cells by tumour necrosis factor. Nature 1995 377 6547 348 351 2-s2.0-0029112253
24. Rahman M. M., McFadden G., Modulation of tumor necrosis factor by microbial pathogens. PLoS Pathogens 2006 2 2, article e4 2-s2.0-39049195635 10.1371/journal.ppat.0020004
25. Herbein G., Montaner L. J., Gordon S., Tumor necrosis factor alpha inhibits entry of human immunodeficiency virus type 1 into primary human macrophages: a selective role for the 75- kilodalton receptor. Journal of Virology 1996 70 11 7388 7397 2-s2.0-0029795271 (Pubitemid 26339043)
26. Karsten V., Gordon S., Kirn A., Herbein G., HIV-1 envelope glycoprotein gp120 down-regulates CD4 expression in primary human macrophages through induction of endogenous tumour necrosis factor- α Immunology 1996 88 1 55 60 2-s2.0-0029886827 (Pubitemid 26166376)
27. Herbein G., Doyle A. G., Montaner L. J., Gordon S., Lipopolysaccharide (LPS) down-regulates CD4 expression in primary human macrophages through induction of endogenous tumour necrosis factor (TNF) and IL-1 β Clinical and Experimental Immunology 1995 102 2 430 437 2-s2.0-0028894811
28. Di Marzio P., Tse J., Landau N. R., Chemokine receptor regulation and HIV type 1 tropism in monocyte-macrophages. AIDS Research and Human Retroviruses 1998 14 2 129 138 2-s2.0-0031882782 (Pubitemid 28063523)
29. Duh E. J., Maury W. J., Folks T. M., Fauci A. S., Rabson A. B., Tumor necrosis factor α activates human immunodeficiency virus type 1 through induction of nuclear factor binding to the NF- B sites in the long terminal repeat. Proceedings of the National Academy of Sciences of the United States of America 1989 86 15 5974 5978 2-s2.0-0001488150 (Pubitemid 19217570)
30. Griffin G. E., Leung K., Folks T. M., Kunkel S., Nabel G. J., Activation of HIV gene expression during monocyte differentiation by induction of NF- B. Nature 1989 339 6219 70 73 2-s2.0-0024502041 (Pubitemid 19115896)
31. Okamoto T., Matsuyama T., Mori S., Hamamoto Y., Kobayashi N., Yamamoto N., Josephs S. F., Wong-Staal F., Shimotohno K., Augmentation of human immunodeficiency virus type 1 gene expression by tumor necrosis factor α AIDS Research and Human Retroviruses 1989 5 2 131 138 2-s2.0-0024538721 (Pubitemid 19116042)
32. Osborn L., Kunkel S., Nabel G. J., Tumor necrosis factor α and interleukin 1 stimulate the human immunodeficiency virus enhancer by activation of the nuclear factor B. Proceedings of the National Academy of Sciences of the United States of America 1989 86 7 2336 2340 2-s2.0-0342742310 (Pubitemid 19102503)
33. Takahashi Y., Tanaka Y., Yamashita A., Koyanagi Y., Nakamura M., Yamamoto N., OX40 stimulation by gp34/OX40 ligand enhances productive human immunodeficiency virus type 1 infection. Journal of Virology 2001 75 15 6748 6757 2-s2.0-0034953586 10.1128/JVI.75.15.6748-6757.2001 (Pubitemid 32641560)
34. Herbein G., Gordon S., 55- and 75-kilodalton tumor necrosis factor receptors mediate distinct actions in regard to human immunodeficiency virus type 1 replication in primary human macrophages. Journal of Virology 1997 71 5 4150 4156 2-s2.0-0030896204 (Pubitemid 27172437)
35. Lane B. R., Markovitz D. M., Woodford N. L., Rochford R., Strieter R. M., Coffey M. J., TNF- α inhibits HIV-1 replication in peripheral blood monocytes and alveolar macrophages by inducing the production of RANTES and decreasing C-C chemokine receptor 5 (CCR5) expression. Journal of Immunology 1999 163 7 3653 3661 2-s2.0-0033215122 (Pubitemid 29450886)
36. Coffey M. J., Woffendin C., Phare S. M., Strieter R. M., Markovitz D. M., RANTES inhibits HIV-1 replication in human peripheral blood monocytes and alveolar macrophages. American Journal of Physiology-Lung Cellular and Molecular Physiology 1997 272 5 part 1 L1025 L1029 2-s2.0-0030940317
37. Simmons G., Clapham P. R., Picard L., Offord R. E., Rosenkilde M. M., Schwartz T. W., Buser R., Wells T. N. C., Proudfoot A. E. I., Potent inhibition of HIV-1 infectivity in macrophages and lymphocytes by a novel CCR5 antagonist. Science 1997 276 5310 276 279 2-s2.0-0030951442 10.1126/science.276.5310.276 (Pubitemid 27172690)
38. McManus C. M., Brosnan C. F., Berman J. W., Cytokine induction of MIP-1 α and MIP-1 β in human fetal microglia. Journal of Immunology 1998 160 3 1449 1455 2-s2.0-0031892523 (Pubitemid 28093447)
39. Kitai R., Zhao M., Zhang N., Hua L. L., Lee S. C., Role of MIP-1 β and RANTES in HIV-1 infection of microglia: inhibition of infection and induction by IFN β Journal of Neuroimmunology 2000 110 1-2 230 239 2-s2.0-0034596585 10.1016/S0165-5728(00)00315-5
40. + T cells is mediated by macrophages through interaction of HIV gp120 with chemokine receptor CXCR4. Nature 1998 395 6698 189 194 2-s2.0-0032505065 10.1038/26026 (Pubitemid 28425660)
41. Sastry K. J., Reddy R. H. R., Pandita R., Totpal K., Aggarwal B. B., HIV-1 tat gene induces tumor necrosis factor- β (lymphotoxin) in a human B-lymphoblastoid cell line. The Journal of Biological Chemistry 1990 265 33 20091 20093 2-s2.0-0025203763 (Pubitemid 120013979)
42. Ensoli B., Barillari G., Salahuddin S. Z., Gallo R. C., Wong-Staal F., Tat protein of HIV-1 stimulates growth of cells derived from Kaposi's sarcoma lesions of AIDS patients. Nature 1990 345 6270 84 86 2-s2.0-0025344596 10.1038/345084a0 (Pubitemid 20152458)
43. Tang Q., Qin D., Lv Z., Zhu X., Ma X., Yan Q., Zeng Y., Guo Y., Feng N., Lu C., Herpes simplex virus type 2 triggers reactivation of Kaposi's sarcoma-associated herpesvirus from latency and collaborates with HIV-1 tat. PLoS ONE 2012 7 2 2-s2.0-84856778889 10.1371/journal.pone.0031652 e31652
44. Graf D., Müller S., Korthäuer U., van Kooten C., Weise C., Kroczek R. A., A soluble form of TRAP (CD40 ligand) is rapidly released after T cell activation. European Journal of Immunology 1995 25 6 1749 1754 2-s2.0-0029051542 10.1002/eji.1830250639
45. van Kooten G., Banchereau J., CD40-CD40 ligand. Journal of Leukocyte Biology 2000 67 1 2 17 2-s2.0-0004535499 (Pubitemid 30046812)
46. Sui Z., Sniderhan L. F., Schifitto G., Phipps R. P., Gelbard H. A., Dewhurst S., Maggirwar S. B., Functional synergy between CD40 ligand and HIV-1 Tat contributes to inflammation: implications in HIV type 1 dementia. Journal of Immunology 2007 178 5 3226 3236 2-s2.0-33847411179 (Pubitemid 46333205)
47. Mazzei G. J., Edgerton M. D., Losberger C., Lecoanet-Henchoz S., Graber P., Durandy A., Gauchat J.-F., Bernard A., Allet B., Bonnefoy J.-Y., Recombinant soluble trimeric CD40 ligand is biologically active. The Journal of Biological Chemistry 1995 270 13 7025 7028 2-s2.0-0028905489 10.1074/jbc.270.13.7025
48. + T-cell counts. Clinical and Diagnostic Laboratory Immunology 2002 9 3 558 561 2-s2.0-0036101654 10.1128/CDLI.9.3.558-561.2002 (Pubitemid 34538213)
49. D'Aversa T. G., Eugenin E. A., Berman J. W., NeuroAIDS: contributions of the human immunodeficiency virus-1 proteins Tat and gp120 as well as CD40 to microglial activation. Journal of Neuroscience Research 2005 81 3 436 446 2-s2.0-25444487187 10.1002/jnr.20486 (Pubitemid 41359298)
50. Ahmad R., Iannello A., Samarani S., Morisset R., Toma E., Grosley M., Ahmad A., Contribution of platelet activation to plasma IL-18 concentrations in HIV-infected AIDS patients. AIDS 2006 20 14 1907 1909 2-s2.0-33748515662 10.1097/01.aids.0000244217.46445.45 (Pubitemid 44358916)
51. Holme P. A., Müller F., Solum N. O., Brosstad F., Froland S. S., Aukrust P., Enhanced activation of platelets with abnormal release of RANTES in human immunodeficiency virus type 1 infection. The FASEB Journal 1998 12 1 79 89 2-s2.0-2642649518
52. Wang J., Zhang W., Nardi M. A., Li Z., HIV-1 Tat-induced platelet activation and release of CD154 contribute to HIV-1-associated autoimmune thrombocytopenia. Journal of Thrombosis and Haemostasis 2011 9 3 562 573 2-s2.0-79952065234 10.1111/j.1538-7836.2010.04168.x
53. Campbell G. R., Pasquier E., Watkins J., Bourgarel-Rey V., Peyrot V., Esquieu D., Barbier P., De Mareuil J., Braguer D., Kaleebu P., Yirrell D. L., Loret E. P., The glutamine-rich region of the HIV-1 Tat protein is involved in T-cell apoptosis. The Journal of Biological Chemistry 2004 279 46 48197 48204 2-s2.0-9144257950 10.1074/jbc.M406195200 (Pubitemid 39540975)
54. Zhang M., Li X., Pang X., Ding L., Wood O., Clouse K., Hewlett I., Dayton A. I., Identification of a potential HIV-induced source of bystander-mediated apoptosis in T cells: upregulation of TRAIL in primary human macrophages by HIV-1 Tat. Journal of Biomedical Science 2001 8 3 290 296 2-s2.0-0034986360 10.1159/000054045 (Pubitemid 32511112)
55. Poonia B., Pauza C. D., Salvato M. S., Role of the Fas/FasL pathway in HIV or SIV disease. Retrovirology 2009 6, article 91 2-s2.0-71149112777 10.1186/1742-4690-6-91
56. Martin G., Tremblay M. J., HLA-DR, ICAM-1, CD40, CD40L, and CD86 are incorporated to a similar degree into clinical human immunodeficiency virus type 1 variants expanded in natural reservoirs such as peripheral blood mononuclear cells and human lymphoid tissue cultured ex vivo. Clinical Immunology 2004 111 3 275 285 2-s2.0-2942560774 10.1016/j.clim.2004.02.004 (Pubitemid 38739321)
57. + T cells. Journal of Virology 2007 81 11 5872 5881 2-s2.0-34249824611 10.1128/JVI.02542-06 (Pubitemid 46847024)
58. Imbeault M., Ouellet M., Giguère K., Bertin J., Bélanger D., Martin G., Tremblay M. J., Acquisition of host-derived CD40L by HIV-1 in vivo and its functional consequences in the B-cell compartment. Journal of Virology 2011 85 5 2189 2200 2-s2.0-79551707880 10.1128/JVI.01993-10
59. Swingler S., Brichacek B., Jacque J., Ulich C., Zhou J., Stevenson M., HIV-1 Nef intersects the macrophage CD40L signalling pathway to promote resting-cell infection. Nature 2003 424 6945 213 219 2-s2.0-0038342442 10.1038/nature01749 (Pubitemid 36858691)
60. Mackay F., Majeau G. R., Lawton P., Hochman P. S., Browning J. L., Lymphotoxin but not tumor necrosis factor functions to maintain splenic architecture and humoral responsiveness in adult mice. European Journal of Immunology 1997 27 8 2033 2042 2-s2.0-0030806321 10.1002/eji.1830270830 (Pubitemid 27346021)
61. Murphy M., Walter B. N., Pike-Nobile L., Fanger N. A., Guyre P. M., Browning J. L., Ware C. F., Epstein L. B., Expression of the lymphotoxin β receptor on follicular stromal cells in human lymphoid tissues. Cell Death and Differentiation 1998 5 6 497 505 2-s2.0-0031847335 (Pubitemid 28356568)
62. Marshall W. L., Brinkman B. M. N., Ambrose C. M., Pesavento P. A., Uglialoro A. M., Teng E., Finberg R. W., Browning J. L., Goldfeld A. E., Signaling through the lymphotoxin- β receptor stimulates HIV-1 replication alone and in cooperation with soluble or membrane-bound TNF- α Journal of Immunology 1999 162 10 6016 6023 2-s2.0-0033562999 (Pubitemid 29314959)
63. Locksley R. M., Killeen N., Lenardo M. J., The TNF and TNF receptor superfamilies: integrating mammalian biology. Cell 2001 104 4 487 501 2-s2.0-0035936797 10.1016/S0092-8674(01)00237-9 (Pubitemid 32201945)
64. Dejardin E., Droin N. M., Delhase M., Haas E., Cao Y., Makris C., Li Z., Karin M., Ware C. F., Green D. R., The lymphotoxin- β receptor induces different patterns of gene expression via two NF- B pathways. Immunity 2002 17 4 525 535 2-s2.0-18644380147 10.1016/S1074-7613(02)00423-5 (Pubitemid 35223540)
65. Wang C., Watts T. H., Maintaining the balance: costimulatory TNFRs and control of HIV. Cytokine & Growth Factor Reviews 2012 23 4-5 245 254
66. Camerini D., Walz G., Loenen W. A. M., Borst J., Seed B., The T cell activation antigen CD27 is a member of the nerve growth factor/tumor necrosis factor receptor gene family. Journal of Immunology 1991 147 9 3165 3169 2-s2.0-0026075319
67. Libregts S., van Olffen R. W., van der Sluijs K. F., van Lier R. A. W., Nolte M. A., Function of CD27 in helper T cell differentiation. Immunology Letters 2011 136 2 177 186 2-s2.0-79953023872 10.1016/j.imlet.2011.01.008
68. Ohmori R., Tsuruyama T., In vitro HIV-1 LTR integration into T-cell activation gene CD27 segment and the decoy effect of modified-sequence DNA. PLoS ONE 2012 7 11 e49960
69. Schröder A. R. W., Shinn P., Chen H., Berry C., Ecker J. R., Bushman F., HIV-1 integration in the human genome favors active genes and local hotspots. Cell 2002 110 4 521 529 2-s2.0-0037162715 10.1016/S0092-8674(02)00864- 4 (Pubitemid 35232295)
70. Durkop H., Latza U., Hummel M., Eitelbach F., Seed B., Stein H., Molecular cloning and expression of a new member of the nerve growth factor receptor family that is characteristic for Hodgkin's disease. Cell 1992 68 3 421 427 2-s2.0-0026601968 10.1016/0092-8674(92)90180-K
71. + T cells producing Th2-type cytokines. The FASEB Journal 1995 9 1 81 86 2-s2.0-0028887624
72. Tsitsikov E. N., Wright D. A., Geha R. S., CD30 induction of human immunodeficiency virus gene transcription is mediated by TRAF2. Proceedings of the National Academy of Sciences of the United States of America 1997 94 4 1390 1395 2-s2.0-0031030693 10.1073/pnas.94.4.1390 (Pubitemid 27087861)
73. Shanebeck K. D., Maliszewski C. R., Kennedy M. K., Picha K. S., Smith C. A., Goodwin R. G., Grabstein K. H., Regulation of murine B cell growth and differentiation by CD30 ligand. European Journal of Immunology 1995 25 8 2147 2153 2-s2.0-0029150257 10.1002/eji.1830250805
74. Biswas P., Smith C. A., Goletti D., Hardy E. C., Jackson R. W., Fauci A. S., Cross-linking of CD30 induces HIV expression in chronically infected T cells. Immunity 1995 2 6 587 596 2-s2.0-0029023638
75. + cells from HIV-infected individuals. Immunity 1995 3 2 251 255 2-s2.0-0029144815
76. Dianzani U., Bensi T., Savarino A., Sametti S., Indelicato M., Mesturini R., Chiocchetti A., Role of FAS in HIV infection. Current HIV Research 2003 1 4 405 417 2-s2.0-2142757377
77. + T cells in vitro and in vivo: association with Fas-mediated apoptosis and modulation by aurintricarboxylic acid. Immunology 1996 87 4 581 585 2-s2.0-0029967552 (Pubitemid 26116467)
78. Cummins N. W., Badley A. D., Mechanisms of HIV-associated lymphocyte apoptosis: 2010. Cell Death and Disease 2010 1 11, article e99 2-s2.0-79957888573 10.1038/cddis.2010.77
79. Kottilil S., Jackson J. O., Reitano K. N., O'Shea M. A., Roby G., Lloyd M., Yang J., Hallahan C. W., Rehm C. A., Arthos J., Lempicki R., Fauci A. S., Innate immunity in HIV infection: enhanced susceptibility to CD95-mediated natural killer cell death and turnover induced by HIV viremia. Journal of Acquired Immune Deficiency Syndromes 2007 46 2 151 159 2-s2.0-34748832264 10.1097/QAI.0b013e3180dc9909 (Pubitemid 47482610)
80. Badley A. D., McElhinny J. A., Leibson P. J., Lynch D. H., Alderson M. R., Paya C. V., Upregulation of fas ligand expression by human immunodeficiency virus in human macrophages mediates apoptosis of uninfected T lymphocytes. Journal of Virology 1996 70 1 199 206 2-s2.0-0029655757 (Pubitemid 126508786)
81. Wang S., Kim Y., Bick C., Kim S. H., Kwon B. S., The potential roles of 4-1BB costimulation in HIV type 1 infection. AIDS Research and Human Retroviruses 1998 14 3 223 231 2-s2.0-0032501953 (Pubitemid 28084016)
82. Takahashi Y., Tanaka R., Yamamoto N., Tanaka Y., Enhancement of OX40-induced apoptosis by TNF coactivation in OX40-expressing T cell lines in vitro leading to decreased targets for HIV type 1 production. AIDS Research and Human Retroviruses 2008 24 3 423 435 2-s2.0-41449093302 10.1089/aid.2007.0092 (Pubitemid 351457738)
83. Tanaka R., Takahashi Y., Kodama A., Saito M., Ansari A. A., Tanaka Y., Suppression of CCR5-tropic HIV type 1 infection by OX40 stimulation via enhanced production of β -chemokines. AIDS Research and Human Retroviruses 2010 26 10 1147 1154 2-s2.0-77958164947 10.1089/aid.2010.0043
84. Herbeuval J., Boasso A., Grivel J., Hardy A. W., Anderson S. A., Dolan M. J., Chougnet C., Lifson J. D., Shearer G. M., TNF-related apoptosis-inducing ligand (TRAIL) in HIV-1-infected patients and its in vitro production by antigen-presenting cells. Blood 2005 105 6 2458 2464 2-s2.0-15244358107 10.1182/blood-2004-08-3058 (Pubitemid 40387046)
85. Kogan M., Deshmane S., Sawaya B. E., Gracely E. J., Khalili K., Rappaport J., Inhibition of NF-kappaB activity by HIV-1 Vpr is dependent on Vpr binding protein. Journal of Cellular Physiology 2013 228 4 781 790
86. Malim M. H., Emerman M., HIV-1 accessory proteins-ensuring viral survival in a hostile environment. Cell Host and Microbe 2008 3 6 388 398 2-s2.0-44649139364 10.1016/j.chom.2008.04.008 (Pubitemid 351784365)
87. Hoshino S., Konishi M., Mori M., Shimura M., Nishitani C., Kuroki Y., Koyanagi Y., Kano S., Itabe H., Ishizaka Y., HIV-1 Vpr induces TLR4/MyD88-mediated IL-6 production and reactivates viral production from latency. Journal of Leukocyte Biology 2010 87 6 1133 1143 2-s2.0-77953977025 10.1189/jlb.0809547
88. Levy D. N., Refaeli Y., Macgregor R. R., Weiner D. B., Serum Vpr regulates productive infection and latency of human immunodeficiency virus type 1. Proceedings of the National Academy of Sciences of the United States of America 1994 91 23 10873 10877 2-s2.0-0028116938 10.1073/pnas.91.23.10873 (Pubitemid 24349587)
89. Varin A., Decrion A., Sabbah E., Quivy V., Sire J., van Lint C., Roques B. P., Aggarwal B. B., Herbein G., Synthetic Vpr protein activates activator protein-1, c-Jun N-terminal kinase, and NF- B and stimulates HIV-1 transcription in promonocytic cells and primary macrophages. The Journal of Biological Chemistry 2005 280 52 42557 42567 2-s2.0-30044438704 10.1074/jbc.M502211200 (Pubitemid 43049213)
90. Roux P., Alfieri C., Hrimech M., Cohen E. A., Tanner J. E., Activation of transcription factors NF- B and NF-IL-6 by human immunodeficiency virus type 1 protein R (Vpr) induces interleukin-8 expression. Journal of Virology 2000 74 10 4658 4665 2-s2.0-0034002849 10.1128/JVI.74.10.4658-4665.2000 (Pubitemid 30237891)
91. Sawaya B. E., Khalili K., Gordon J., Taube R., Amini S., Cooperative interaction between HIV-1 regulatory proteins Tat and Vpr modulates transcription of the viral genome. The Journal of Biological Chemistry 2000 275 45 35209 35214 2-s2.0-0034634585 10.1074/jbc.M005197200
92. Kumar A., Manna S. K., Dhawan S., Aggarwal B. B., HIV-Tat protein activates c-Jun N-terminal kinase and activator protein-1. Journal of Immunology 1998 161 2 776 781 2-s2.0-0032528334 (Pubitemid 28323541)
93. Muthumani K., Choo A. Y., Zong W., Madesh M., Hwang D. S., Premkumar A., Thieu K. P., Emmanuel J., Kumar S., Thompson C. B., Weiner D. B., The HIV-1 Vpr and glucocorticoid receptor complex is a gain-of-function interaction that prevents the nuclear localization of PARP-1. Nature Cell Biology 2006 8 2 170 179 2-s2.0-33645147708 10.1038/ncb1352
94. + T cells. Traffic 2010 11 1 110 122 2-s2.0-71849085384 10.1111/j.1600-0854.2009. 01006.x
95. Das S. R., Jameel S., Biology of the HIV Nef protein. Indian Journal of Medical Research 2005 121 4 315 332 2-s2.0-18844363668 (Pubitemid 40691366)
96. Olivetta E., Percario Z., Fiorucci G., Mattia G., Schiavoni I., Dennis C., Jäger J., Harris M., Romeo G., Affabris E., Federico M., HIV-1 Nef induces the release of inflammatory factors from human monocyte/macrophages: involvement of Nef endocytotic signals and NF- B activation. Journal of Immunology 2003 170 4 1716 1727 2-s2.0-0037441996 (Pubitemid 36197386)
97. Mangino G., Percario Z. A., Fiorucci G., Vaccari G., Manrique S., Romeo G., Federico M., Geyer M., Affabris E., In vitro treatment of human monocytes/macrophages with myristoylated recombinant Nef of human immunodeficiency virus type 1 leads to the activation of mitogen-activated protein kinases, I B kinases, and interferon regulatory factor 3 and to the release of beta interferon. Journal of Virology 2007 81 6 2777 2791 2-s2.0-33947390903 10.1128/JVI.01640-06 (Pubitemid 46447042)
98. Varin A., Manna S. K., Quivy V., Decrion A., van Lint C., Herbein G., Aggarwal B. B., Exogenous Nef protein activates NF- B, AP-1, and c-Jun N-terminal kinase and stimulates HIV transcription in promonocytic cells: role in AIDS pathogenesis. The Journal of Biological Chemistry 2003 278 4 2219 2227 2-s2.0-0037462825 10.1074/jbc.M209622200 (Pubitemid 36801289)
99. Decrion A. Z., Dichamp I., Varin A., Herbein G., HIV and inflammation. Current HIV Research 2005 3 3 243 259 2-s2.0-22944442240 10.2174/ 1570162054368057 (Pubitemid 41052424)
100. Croft M., Benedict C. A., Ware C. F., Clinical targeting of the TNF and TNFR superfamilies. Nature Reviews Drug Discovery 2013 12 2 147 168
101. Knight D. M., Trinh H., Le J., Siegel S., Shealy D., McDonough M., Scallon B., Moor M. A., Vilcek J., Daddona P., Ghrayeb J., Construction and initial characterization of a mouse-human chimeric anti-TNF antibody. Molecular Immunology 1993 30 16 1443 1453 2-s2.0-0027361432 10.1016/0161-5890(93)90106-L
102. Goel N., Stephens S., Certolizumab pegol. MAbs 2010 2 2 137 147 2-s2.0-77953660821 10.4161/mabs.2.2.11271
103. Aukrust P., Liabakk N., Müller F., Lien E., Espevik T., Frøland S. S., Serum levels of tumor necrosis factor- α (TNF α) and soluble TNF receptors in human immunodeficiency virus type 1 infection-correlations to clinical, immunologic, and virologic parameters. Journal of Infectious Diseases 1994 169 2 420 424 2-s2.0-0028140219 (Pubitemid 24045606)
104. Whalen C., Horsburgh C. R., Hom D., Lahart C., Simberkoff M., Ellner J., Accelerated course of human immunodeficiency virus infection after tuberculosis. American Journal of Respiratory and Critical Care Medicine 1995 151 1 129 135 2-s2.0-0028852604
105. Dezube B. J., Lederman M. M., Chapman B., Georges D. L., Dogon A. L., Mudido P., Reis-Lishing J., Cheng S., Silberman S. L., Crumpacker C. S., The effect of tenidap on cytokines, acute-phase proteins, and virus load in human immunodeficiency virus (HIV)-infected patients: correlation between plasma HIV-1 RNA and proinflammatory cytokine levels. Journal of Infectious Diseases 1997 176 3 807 810 2-s2.0-16944363271 (Pubitemid 27360558)
106. Valdez H., Lederman M. M., Cytokines and cytokine therapies in HIV infection. AIDS Clinical Review 1997 187 228 2-s2.0-0030630914
107. Marriott J. B., Cookson S., Carlin E., Youle M., Hawkins D. A., Nelson M., Pearson M., Vaughan A. N., Gazzard B., Dalgleish A. G., A double-blind placebo-controlled phase II trial of thalidomide in asymptomatic HIV-positive patients: clinical tolerance and effect on activation markers and cytokines. AIDS Research and Human Retroviruses 1997 13 18 1625 1631 2-s2.0-0031459383 (Pubitemid 28009368)
108. Wallis R. S., Nsubuga P., Whalen C., Mugerwa R. D., Okwera A., Oette D., Jackson J. B., Johnson J. L., Ellner J. J., Pentoxifylline therapy in human immunodeficiency virus-seropositive persons with tuberculosis: a randomized, controlled trial. Journal of Infectious Diseases 1996 174 4 727 733 2-s2.0-0029813078 (Pubitemid 26325887)
109. Haraguchi S., Day N. K., Kamchaisatian W., Beigier-Pompadre M., Stenger S., Tangsinmankong N., Sleasman J. W., Pizzo S. V., Cianciolo G. J., LMP-420, a small-molecule inhibitor of TNF-alpha, reduces replication of HIV-1 and Mycobacterium tuberculosis in human cells. AIDS Research and Therapy 2006 3 1, article 8 2-s2.0-33748169679 10.1186/1742-6405-3-8 (Pubitemid 44309021)
110. Ting P. T., Koo J. Y., Use of etanercept in human immunodeficiency virus (HIV) and acquired immunodeficiency syndrome (AIDS) patients. International Journal of Dermatology 2006 45 6 689 692 2-s2.0-33745960966 10.1111/j.1365-4632. 2005.02642.x (Pubitemid 44056670)
111. Calabrese L. H., Zein N., Vassilopoulos D., Safety of antitumour necrosis factor (anti-TNF) therapy in patients with chronic viral infections: hepatitis C, hepatitis B, and HIV infection. Annals of the Rheumatic Diseases 2004 63 supplement 2 ii18 ii24 2-s2.0-7044270670 10.1136/ard.2004.028209 (Pubitemid 39424653)
112. Sha B. E., Ogata-Arakaki D. M., Fox L., Estep S., Erice A., Kilgo P., Walker R. E., Bancroft L., Lederman M. M., Valdez H., Gelman R. S., Landay A. L., Agosti J., Mitsuyasu R., Pollard R. B., Mildvan D., Namkung A., Effect of etanercept (enbrel) on interleukin 6, tumor necrosis factor, and markers of immune activation in HIV-infected subjects receiving interleukin 2. AIDS Research and Human Retroviruses 2002 18 9 661 665 2-s2.0-0036434120 10.1089/088922202760019365 (Pubitemid 35356586)
113. Wallis R. S., Kyambadde P., Johnson J. L., Horter L., Kittle R., Pohle M., Ducar C., Millard M., Mayanja-Kizza H., Whalen C., Okwera A., A study of the safety, immunology, virology, and microbiology of adjunctive etanercept in HIV-1-associated tuberculosis. AIDS 2004 18 2 257 264 2-s2.0-10744233930 10.1097/00002030-200401230-00015 (Pubitemid 38253448)
114. Walker R. E., Spooner K. M., Kelly G., McCloskey R. V., Woody J. N., Falloon J., Baseler M., Piscitelli S. C., Davey R. T. Jr., Polis M. A., Kovacs J. A., Masur H., Clifford Lane H., Inhibition of immunoreactive tumor necrosis factor- α by a chimeric antibody in patients infected with human immunodeficiency virus type 1. Journal of Infectious Diseases 1996 174 1 63 68 2-s2.0-19244364119 (Pubitemid 26255555)
115. Gaylis N., Infliximab in the treatment of an HIV positive patient with Reiter's syndrome. Journal of Rheumatology 2003 30 2 407 411 2-s2.0-0037308218 (Pubitemid 36152613)
116. Cepeda E. J., Williams F. M., Ishimori M. L., Weisman M. H., Reveille J. D., The use of anti-tumour necrosis factor therapy in HIV-positive individuals with rheumatic disease. Annals of the Rheumatic Diseases 2008 67 5 710 712 2-s2.0-42449137846 10.1136/ard.2007.081513 (Pubitemid 351571938)
117. Wang C., Wen T., Routy J., Bernard N. F., Sekaly R. P., Watts T. H., 4-1BBL induces TNF receptor-associated factor 1-dependent Bim modulation in human T cells and is a critical component in the costimulation-dependent rescue of functionally impaired HIV-specific CD8 T cells. Journal of Immunology 2007 179 12 8252 8263 2-s2.0-40049091217
118. + T regulatory cell inhibition. Journal of Immunology 2006 176 4 2486 2495 2-s2.0-32144453848 (Pubitemid 43204485)
119. Cannons J. L., Lau P., Ghumman B., DeBenedette M. A., Yagita H., Okumura K., Watts T. H., 4-1BB ligand induces cell division, sustains survival, and enhances effector function of CD4 and CD8 T cells with similar efficacy. Journal of Immunology 2001 167 3 1313 1324 2-s2.0-0035423265 (Pubitemid 32703127)
120. Taraban V. Y., Rowley T. F., O'Brien L., Expression and costimulatory effects of the TNF receptor superfamily members CD134 (OX40) and CD137 (4-1BB), and their role in the generation of anti-tumor immune responses. European Journal of Immunology 2002 32 12 3617 3627 (Pubitemid 36024398)
121. Watts T. H., TNF/TNFR family members in costimulation of T cell responses. Annual Review of Immunology 2005 23 23 68 2-s2.0-17644389199 10.1146/annurev.immunol.23.021704.115839 (Pubitemid 40563164)
122. Serghides L., Bukczynski J., Wen T., Wang C., Routy J., Boulassel M.,
123. Ascierto P. A., Simeone E., Sznol M., Fu Y., Melero I., Clinical experiences with anti-CD137 and anti-PD1 therapeutic antibodies. Seminars in Oncology 2010 37 5 508 516 2-s2.0-78449237499 10.1053/j.seminoncol.2010.09.008
124. Lee S., Salek-Ardakani S., Mittler R. S., Croft M., Hypercostimulation through 4-1BB distorts homeostasis of immune cells. Journal of Immunology 2009 182 11 6753 6762 2-s2.0-67449126825 10.4049/jimmunol.0803241
125. Harrison J. M., Bertram E. M., Boyle D. B., Coupar B. E. H., Ranasinghe C., Ramshaw I. A., 4-1BBL coexpression enhances HIV-specific CD8 T cell memory in a poxvirus prime-boost vaccine. Vaccine 2006 24 47-48 6867 6874 2-s2.0-33846070524 10.1016/j.vaccine.2006.06.007 (Pubitemid 46107184)
126. Chun T., Fauci A. S., Latent reservoirs of HIV: obstacles to the eradication of virus. Proceedings of the National Academy of Sciences of the United States of America 1999 96 20 10958 10961 2-s2.0-0033613070 10.1073/pnas.96.20.10958 (Pubitemid 29487311)
127. Chomont N., El-Far M., Ancuta P., Trautmann L., Procopio F. A., Yassine-Diab B., Boucher G., Boulassel M., Ghattas G., Brenchley J. M., Schacker T. W., Hill B. J., Douek D. C., Routy J., Haddad E. K., Sékaly R., HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation. Nature Medicine 2009 15 8 893 900 2-s2.0-68349139711 10.1038/nm.1972
128. Abbas W., Herbein G., Molecular understanding of HIV-1 latency. Advances in Virology 2012 2012 14 574967 10.1155/2012/574967
129. + T cells within the gut lamina propria requires OX40 and CD30 signals. Journal of Immunology 2009 183 8 5079 5084 2-s2.0-77954116318 10.4049/jimmunol.0901514
130. + T cells using a combination of cytokines. Journal of Experimental Medicine 1998 188 1 83 91 2-s2.0-0032490570 10.1084/jem.188.1.83 (Pubitemid 28328608)
131. Reuse S., Calao M., Kabeya K., Guiguen A., Gatot J., Quivy V., Vanhulle C., Lamine A., Vaira D., Demonte D., Martinelli V., Veithen E., Cherrier T., Avettand V., Poutrel S., Piette J., de Launoit Y., Moutschen M., Burny A., Rouzioux C., De Wit S., Herbein G., Rohr O., Collette Y., Lambotte O., Clumeck N., van Lint C., Synergistic activation of HIV-1 expression by deacetylase inhibitors and prostratin: implications for treatment of latent infection. PLoS ONE 2009 4 6 2-s2.0-67650550767 10.1371/journal.pone.0006093 e6093
132. Chan J. K. L., Greene W. C., NF- B/Rel: agonist and antagonist roles in HIV-1 latency. Current Opinion in HIV and AIDS 2011 6 1 12 18 2-s2.0-79954438684 10.1097/COH.0b013e32834124fd
133. Burnett J. C., Lim K., Calafi A., Rossi J. J., Schaffer D. V., Arkin A. P., Combinatorial latency reactivation for HIV-1 subtypes and variants. Journal of Virology 2010 84 12 5958 5974 2-s2.0-77952698531 10.1128/JVI.00161-10
134. Quivy V., Adam E., Collette Y., Demonte D., Chariot A., Vanhulle C., Berkhout B., Castellano R., De Launoit Y., Burny A., Piette J., Bours V., van Lint C., Synergistic activation of human immunodeficiency virus type 1 promoter activity by NF- B and inhibitors of deacetylases: potential perspectives for the development of therapeutic strategies. Journal of Virology 2002 76 21 11091 11103 2-s2.0-0036839054 10.1128/JVI.76.21.11091-11103.2002 (Pubitemid 35176225)
135. Vandergeeten C., Quivy V., Moutschen M., van Lint C., Piette J., Legrand-Poels S., HIV-1 protease inhibitors do not interfere with provirus transcription and host cell apoptosis induced by combined treatment TNF- α + TSA. Biochemical Pharmacology 2007 73 11 1738 1748 2-s2.0-34247352107 10.1016/j.bcp.2007.02.011 (Pubitemid 46628678)
136. Demonté D., Quivy V., Colette Y., van Lint C., Administration of HDAC inhibitors to reactivate HIV-1 expression in latent cellular reservoirs: implications for the development of therapeutic strategies. Biochemical Pharmacology 2004 68 6 1231 1238 2-s2.0-4143089463 10.1016/j.bcp.2004.05.040 (Pubitemid 39094289)
137. El Kharroubi A., Piras G., Zensen R., Martin M. A., Transcriptional activation of the integrated chromatin-associated human immunodeficiency virus type 1 promoter. Molecular and Cellular Biology 1998 18 5 2535 2544 2-s2.0-0031942998 (Pubitemid 28183423)
138. Berger S. L., Histone modifications in transcriptional regulation. Current Opinion in Genetics and Development 2002 12 2 142 148 2-s2.0-0036532026 10.1016/S0959-437X(02)00279-4 (Pubitemid 34219485)
139. Adam E., Quivy V., Bex F., Potentiation of tumor necrosis factor-induced NF-kappa B activation by deacetylase inhibitors is associated with a delayed cytoplasmic reappearance of I kappa B alpha. Molecular and Cellular Biology 2003 23 17 6200 6209 (Pubitemid 37013097)
140. + T cells from HIV-1+ HAART-treated patients. AIDS 2012 26 12 1473 1482 2-s2.0-84860386745
141. Wolschendorf F., Bosque A., Shishido T., Duverger A., Jones J., Planelles V., Kutsch O., Kinase control prevents HIV-1 reactivation in spite of high levels of induced NF-kappaB activity. Journal of Virology 2012 86 8 4548 4558
142. Cannons J. L., Hoeflich K. P., Woodgett J. R., Watts T. H., Role of the stress kinase pathway in signaling via the T cell costimulatory receptor 4-1BB. Journal of Immunology 1999 163 6 2990 2998 2-s2.0-0033567975 (Pubitemid 29431793)
143. Deeks S. G., Autran B., Berkhout B., Towards an HIV cure: a global scientific strategy. Nature Reviews Immunology 2012 12 8 607 614